

# Alberto Bosi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5022483/publications.pdf>

Version: 2024-02-01

282  
papers

16,535  
citations

13827

67  
h-index

18606

119  
g-index

285  
all docs

285  
docs citations

285  
times ranked

14033  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia. <i>New England Journal of Medicine</i> , 2004, 351, 2276-2285.	13.9	1,058
2	Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). <i>Blood</i> , 2001, 98, 2942-2947.	0.6	487
3	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet</i> , The, 2017, 390, 555-566.	6.3	444
4	Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. <i>Blood</i> , 2007, 110, 840-846.	0.6	419
5	Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). <i>Blood</i> , 2009, 113, 4153-4162.	0.6	387
6	Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. <i>Blood</i> , 2014, 123, 1552-1555.	0.6	346
7	Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. <i>Leukemia</i> , 2007, 21, 1952-1959.	3.3	328
8	Thymoglobulin Prevents Chronic Graft-versus-Host Disease, Chronic Lung Dysfunction, and Late Transplant-Related Mortality: Long-Term Follow-Up of a Randomized Trial in Patients Undergoing Unrelated Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 560-565.	2.0	326
9	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. <i>Blood</i> , 2010, 116, 3171-3179.	0.6	290
10	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. <i>Leukemia</i> , 2014, 28, 1804-1810.	3.3	263
11	Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2003, 31, 481-486.	1.3	247
12	EZH2 mutational status predicts poor survival in myelofibrosis. <i>Blood</i> , 2011, 118, 5227-5234.	0.6	242
13	Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. <i>Leukemia</i> , 2005, 19, 1847-1849.	3.3	236
14	Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. <i>Haematologica</i> , 2018, 103, 2079-2087.	1.7	225
15	Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. <i>Blood</i> , 2008, 112, 844-847.	0.6	216
16	The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. <i>Haematologica</i> , 2006, 91, 475-81.	1.7	213
17	Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. <i>Blood</i> , 2016, 127, 2833-2840.	0.6	207
18	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 3627-3637.	0.8	204

#	ARTICLE	IF	CITATIONS
19	Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. <i>Leukemia</i> , 2015, 29, 1891-1900.	3.3	199
20	Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. <i>Blood</i> , 2009, 114, 1477-1483.	0.6	196
21	WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Blood</i> , 2008, 112, 895-902.	0.6	192
22	Second Allogeneic Bone Marrow Transplantation in Acute Leukemia: Results of a Survey by the European Cooperative Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2001, 19, 3675-3684.	0.8	173
23	Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up. <i>Journal of Clinical Oncology</i> , 2011, 29, 3016-3022.	0.8	171
24	Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. <i>Blood</i> , 2013, 121, 5055-5063.	0.6	171
25	Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. <i>Blood</i> , 2014, 123, 2333-2342.	0.6	162
26	Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. <i>Haematologica</i> , 2009, 94, 230-238.	1.7	161
27	Proposed definition of "poor mobilizer"™ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. <i>Bone Marrow Transplantation</i> , 2012, 47, 342-351.	1.3	156
28	Anaemia characterises patients with myelofibrosis harbouring MplW515L/Kmutation. <i>British Journal of Haematology</i> , 2007, 137, 244-247.	1.2	153
29	Treatment of refractory chronic GVHD with rituximab: a GITMO study. <i>Bone Marrow Transplantation</i> , 2007, 40, 273-277.	1.3	152
30	Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. <i>Blood</i> , 2005, 105, 2601-2607.	0.6	147
31	Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. <i>Haematologica</i> , 2008, 93, 41-48.	1.7	146
32	Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. <i>Haematologica</i> , 2010, 95, 476-484.	1.7	144
33	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. <i>Blood</i> , 2011, 118, 2069-2076.	0.6	144
34	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1525-1536.	5.1	143
35	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 872-880.	2.0	141
36	Human polyomavirus BK (BKV) load and haemorrhagic cystitis in bone marrow transplantation patients. <i>Journal of Clinical Virology</i> , 1999, 14, 79-86.	1.6	136

#	ARTICLE	IF	CITATIONS
37	Second malignancy in patients treated for Hodgkin's disease. <i>Cancer</i> , 1980, 46, 1735-1740.	2.0	133
38	Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. <i>Blood</i> , 2009, 114, 1437-1444.	0.6	131
39	Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Haematologica</i> , 2008, 93, 1514-1522.	1.7	121
40	Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. <i>Multiple Sclerosis Journal</i> , 2012, 18, 835-842.	1.4	115
41	Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. <i>Blood</i> , 2010, 116, 335-342.	0.6	112
42	Molecular Profiling of CD34+ Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1). <i>Stem Cells</i> , 2007, 25, 165-173.	1.4	111
43	Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party. <i>British Journal of Haematology</i> , 1993, 83, 145-151.	1.2	107
44	Hydroxyurea-related toxicity in 3,411 patients with Ph <sup>-</sup> negative MPN. <i>American Journal of Hematology</i> , 2012, 87, 552-554.	2.0	105
45	Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2068-2073.	1.1	100
46	Autologous Mesenchymal Stem Cells Foster Revascularization of Ischemic Limbs in Systemic Sclerosis. <i>Annals of Internal Medicine</i> , 2010, 153, 650.	2.0	100
47	Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. <i>Blood</i> , 2012, 120, 1327-1333.	0.6	99
48	Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. <i>Annals of Hematology</i> , 2007, 86, 897-903.	0.8	98
49	Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. <i>Journal of Clinical Oncology</i> , 1991, 9, 432-437.	0.8	97
50	Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). <i>British Journal of Haematology</i> , 2002, 118, 1112-1119.	1.2	97
51	Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes. <i>PLoS ONE</i> , 2011, 6, e23109.	1.1	95
52	Primary cutaneous follicular centre-cell lymphoma-a lymphoproliferative disease with favourable prognosis. <i>Clinical and Experimental Dermatology</i> , 1989, 14, 12-19.	0.6	93
53	Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. <i>Archives of Dermatological Research</i> , 2008, 300, 115-124.	1.1	91
54	Hypermethylation of CXCR4 Promoter in CD34+ Cells from Patients with Primary Myelofibrosis. <i>Stem Cells</i> , 2008, 26, 1920-1930.	1.4	91

#	ARTICLE	IF	CITATIONS
55	Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. <i>British Journal of Haematology</i> , 2005, 128, 738-738.	1.2	89
56	Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. <i>Annals of Oncology</i> , 2013, 24, 2430-2434.	0.6	89
57	Autologous stem cell transplantation improves microcirculation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 94-98.	0.5	88
58	Treatment of Experimental Injury of Anal Sphincters with Primary Surgical Repair and Injection of Bone Marrow-Derived Mesenchymal Stem Cells. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 411-420.	0.7	86
59	Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1999, 24, 47-51.	1.3	84
60	Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. <i>Leukemia</i> , 2014, 28, 621-628.	3.3	80
61	mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms. <i>PLoS ONE</i> , 2013, 8, e54826.	1.1	80
62	Familial Hemophagocytic Lymphohistiocytosis May Present during Adulthood: Clinical and Genetic Features of a Small Series. <i>PLoS ONE</i> , 2012, 7, e44649.	1.1	77
63	ATP Modulates Cell Proliferation and Elicits Two Different Electrophysiological Responses in Human Mesenchymal Stem Cells. <i>Stem Cells</i> , 2007, 25, 1840-1849.	1.4	76
64	Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 617-626.	2.0	75
65	Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. <i>Leukemia</i> , 2014, 28, 1811-1818.	3.3	75
66	Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: A GITMO study. <i>Annals of Hematology</i> , 2012, 91, 931-939.	0.8	74
67	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	0.6	72
68	MicroRNA expression profile in granulocytes from primary myelofibrosis patients. <i>Experimental Hematology</i> , 2007, 35, 1708.e1-1708.e12.	0.2	71
69	Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment. <i>Journal of Neuroimmunology</i> , 2008, 199, 142-150.	1.1	71
70	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)â€”a study of 1084 patients. <i>Leukemia</i> , 2020, 34, 1407-1421.	3.3	68
71	Fatal herpesvirus 6 encephalitis after unrelated bone marrow transplant. <i>Bone Marrow Transplantation</i> , 1998, 22, 285-288.	1.3	66
72	No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. <i>British Journal of Haematology</i> , 2000, 110, 308-314.	1.2	64

#	ARTICLE	IF	CITATIONS
73	Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. <i>British Journal of Haematology</i> , 2005, 130, 271-275.	1.2	63
74	FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. <i>Annals of Oncology</i> , 2015, 26, 2155-2161.	0.6	63
75	Abnormalities of GATA-1 in Megakaryocytes from Patients with Idiopathic Myelofibrosis. <i>American Journal of Pathology</i> , 2005, 167, 849-858.	1.9	62
76	Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2011, 96, 937-942.	1.7	62
77	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 581-588.	2.0	61
78	<i>CEBPA</i> "double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. <i>Haematologica</i> , 2017, 102, 529-540.	1.7	61
79	Human parvovirus B19 infection in bone marrow transplantation patients. <i>American Journal of Hematology</i> , 1993, 44, 207-209.	2.0	59
80	Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process. <i>Transfusion</i> , 2013, 53, 2340-2352.	0.8	59
81	The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. <i>Haematologica</i> , 2009, 94, 1537-1545.	1.7	58
82	Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. <i>Hematological Oncology</i> , 2007, 25, 198-203.	0.8	57
83	Acute leukaemia in patients treated for Hodgkin's disease. <i>British Journal of Haematology</i> , 1984, 58, 43-52.	1.2	55
84	Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA. <i>British Journal of Haematology</i> , 1998, 103, 610-617.	1.2	54
85	Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1080-1088.	2.0	54
86	The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. <i>Leukemia</i> , 2006, 20, 2074-2076.	3.3	51
87	Prophylaxis and Treatment of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Results of a Consensus Process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Clinical Infectious Diseases</i> , 2009, 49, 1226-1236.	2.9	51
88	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. <i>Leukemia</i> , 2017, 31, 2449-2457.	3.3	51
89	Combined surgery and chemotherapy for the treatment of primary gastrointestinal intermediate- or high-grade non-Hodgkin's lymphomas. <i>British Journal of Cancer</i> , 1989, 60, 244-248.	2.9	50
90	Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. <i>British Journal of Haematology</i> , 2006, 134, 54-57.	1.2	50

#	ARTICLE	IF	CITATIONS
91	Insights into JAK2-V617F mutation in CML. <i>Lancet Oncology</i> , The, 2007, 8, 864-866.	5.1	50
92	Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. <i>Bone Marrow Transplantation</i> , 2007, 39, 347-352.	1.3	50
93	The prognostic value of positron emission tomography performed after two courses (<sup>18</sup>F-INTERIM- <sup>18</sup> F-FLT) of standard therapy on treatment outcome in early stage <sup>18</sup>F-FLT-positiv Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). <i>American Journal of Hematology</i> , 2015, 90, 499-503.	2.0	49
94	HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. <i>Bone Marrow Transplantation</i> , 2009, 44, 571-577.	1.3	48
95	Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Societ� Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process. <i>Transfusion</i> , 2012, 52, 893-905.	0.8	48
96	A Sensitive Detection Method for MPLW515L or MPLW515K Mutation in Chronic Myeloproliferative Disorders with Locked Nucleic Acid-Modified Probes and Real-Time Polymerase Chain Reaction. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 435-441.	1.2	47
97	Use of CFDA-SE for evaluating the in vitro proliferation pattern of human mesenchymal stem cells. <i>Cytotherapy</i> , 2006, 8, 243-253.	0.3	46
98	Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas. <i>Annals of Hematology</i> , 2007, 86, 565-568.	0.8	46
99	A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. <i>BMC Cancer</i> , 2008, 8, 195.	1.1	46
100	Safety of Bone Marrow Stem Cell Donation: A Review. <i>Transplantation Proceedings</i> , 2010, 42, 2192-2194.	0.3	46
101	Increase in FOXP3+ Regulatory T Cells in GVHD Skin Biopsies Is Associated with Lower Disease Severity and Treatment Response. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 938-947.	2.0	43
102	Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of �10 years. <i>Bone Marrow Transplantation</i> , 2015, 50, 1508-1512.	1.3	43
103	Displacement of T Lymphocytes with the � Helper/Inducer � Phenotype from Peripheral Blood to Lymphoid Organs in Untreated Patients with Hodgkin's Disease. <i>Scandinavian Journal of Haematology</i> , 1983, 31, 305-314.	0.0	41
104	Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. <i>Haematologica</i> , 2010, 95, 1435-1438.	1.7	41
105	The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. <i>British Journal of Haematology</i> , 2008, 141, 814-819.	1.2	40
106	Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease. <i>Transplantation</i> , 2016, 100, e147-e155.	0.5	40
107	Factors affecting successful mobilization with plerixafor: an <sup>18</sup>F-FLT-italian prospective survey in 215 patients with multiple myeloma and lymphoma. <i>Transfusion</i> , 2014, 54, 331-339.	0.8	39
108	Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2006, 47, 171-173.	0.6	38

#	ARTICLE	IF	CITATIONS
109	Development of human striatal anlagen after transplantation in a patient with Huntington's disease. <i>Experimental Neurology</i> , 2008, 213, 241-244.	2.0	38
110	A life-threatening ruxolitinib discontinuation syndrome. <i>American Journal of Hematology</i> , 2017, 92, 833-838.	2.0	38
111	The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. <i>Leukemia</i> , 2013, 27, 2086-2091.	3.3	37
112	Inorganic nanoparticles as potential regulators of immune response in dendritic cells. <i>Nanomedicine</i> , 2017, 12, 1647-1660.	1.7	37
113	Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients. <i>Annals of Hematology</i> , 2012, 91, 1013-1022.	0.8	36
114	Nephrotic Syndrome and Renal Failure After Allogeneic Stem Cell Transplantation: Novel Molecular Diagnostic Tools for a Challenging Differential Diagnosis. <i>American Journal of Kidney Diseases</i> , 2005, 46, 550-556.	2.1	35
115	Cord blood banking. <i>Vox Sanguinis</i> , 2008, 95, 335-348.	0.7	35
116	JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. <i>Haematologica</i> , 2009, 94, 144-146.	1.7	35
117	Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood—a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Hematology and Oncology</i> , 2015, 8, 107.	6.9	35
118	Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. <i>Haematologica</i> , 2010, 95, 833-836.	1.7	34
119	Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2006, 47, 167-169.	0.6	33
120	Time related variations in stem cell harvesting of umbilical cord blood. <i>Scientific Reports</i> , 2016, 6, 21404.	1.6	33
121	Percutaneous vertebroplasty and kyphoplasty in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2006, 76, 180-181.	1.1	32
122	Concomitant occurrence of BCR-ABL and JAK2V617F mutation. <i>Blood</i> , 2011, 118, 3445-3446.	0.6	32
123	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. <i>Journal of Hematology and Oncology</i> , 2020, 13, 115.	6.9	32
124	Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2016, 122, 1880-1887.	2.0	31
125	Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group. <i>Blood</i> , 2004, 104, 392-392.	0.6	30
126	Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients. <i>Clinical Cancer Research</i> , 2012, 18, 3079-3089.	3.2	29



#	ARTICLE	IF	CITATIONS
127	Comparative Proteomic Analysis of Chronic Myelogenous Leukemia Cells: Inside the Mechanism of Imatinib Resistance. <i>Journal of Proteome Research</i> , 2007, 6, 367-375.	1.8	28
128	Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin) ± rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. <i>Cancer</i> , 2010, 116, 4573-4579.	2.0	28
129	Impaired erythropoietin production in mice treated with cyclosporin A. <i>Blood</i> , 1991, 78, 1615-1618.	0.6	28
130	<sup>18</sup> F-FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results. <i>Oncology Reports</i> , 2005, 14, 1209-14.	1.2	28
131	Treatment-related leukemia in Hodgkin's disease: A multi-institution study on 75 cases. <i>Hematological Oncology</i> , 1987, 5, 83-98.	0.8	26
132	Impact of marrow unrelated donor search duration on outcome of children with acute lymphoblastic leukemia in second remission. <i>Bone Marrow Transplantation</i> , 2003, 32, 325-331.	1.3	26
133	B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. <i>Haematologica</i> , 2007, 92, 258-259.	1.7	26
134	Molecular epidemiological investigation of an outbreak of <i>Pseudomonas aeruginosa</i> infection in an SCT unit. <i>Bone Marrow Transplantation</i> , 2009, 43, 335-338.	1.3	26
135	Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera. <i>Blood</i> , 2011, 117, 6923-6927.	0.6	26
136	Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. <i>American Journal of Hematology</i> , 2012, 87, 1047-1051.	2.0	26
137	Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT. <i>Journal of Internal Medicine</i> , 2018, 283, 178-189.	2.7	26
138	Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. <i>Oncotarget</i> , 2016, 7, 72311-72321.	0.8	26
139	Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. <i>European Journal of Haematology</i> , 2007, 78, 330-337.	1.1	25
140	Peripheral blood blast clearance during induction therapy in acute myeloid leukemia. <i>Blood</i> , 2008, 111, 1746-1747.	0.6	25
141	The conundrum of HLA-DRB1*14:01/*14:54 and HLA-DRB3*02:01/*02:02 mismatches in unrelated hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2011, 46, 916-922.	1.3	25
142	CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease. <i>Haematologica</i> , 2012, 97, 568-571.	1.7	25
143	Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas. <i>European Journal of Haematology</i> , 2014, 93, 129-136.	1.1	25
144	Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment. <i>Hematological Oncology</i> , 2017, 35, 69-78.	0.8	25

#	ARTICLE	IF	CITATIONS
145	Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 932-940.	2.0	25
146	Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. <i>Annals of Oncology</i> , 2005, 16, 228-233.	0.6	24
147	Allogeneic Stem Cell Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 2667-2669.	0.3	24
148	Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases. <i>Multiple Sclerosis Journal</i> , 2007, 13, 676-678.	1.4	24
149	Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. <i>Haematologica</i> , 2013, 98, e101-e102.	1.7	24
150	Experts'™ considerations on HLA-haploidentical stem cell transplantation. <i>European Journal of Haematology</i> , 2014, 93, 187-197.	1.1	24
151	Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , 2017, 52, 163-166.	1.3	24
152	One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab. <i>European Journal of Haematology</i> , 2021, 106, 389-397.	1.1	24
153	Impaired erythropoietin production in mice treated with cyclosporin A. <i>Blood</i> , 1991, 78, 1615-1618.	0.6	23
154	Event-free survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2007, 40, 643-649.	1.3	23
155	Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2009, 94, 102-112.	1.7	23
156	Primary lymphoma of bone: outcome and role of surgery. <i>International Orthopaedics</i> , 2013, 37, 2437-2442.	0.9	23
157	Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. <i>Bone Marrow Transplantation</i> , 1999, 23, 489-495.	1.3	22
158	Significance of CTLA-4 and CD14 genetic polymorphisms in clinical outcome after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2007, 40, 1001-1002.	1.3	22
159	Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. <i>Leukemia</i> , 2010, 24, 1533-1537.	3.3	22
160	Selective ex vivo expansion of cytomegalovirus-specific CD4+ and CD8+ T lymphocytes using dendritic cells pulsed with a human leucocyte antigen A*0201-restricted peptide. <i>British Journal of Haematology</i> , 2001, 113, 479-482.	1.2	21
161	PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. <i>British Journal of Haematology</i> , 2004, 127, 214-219.	1.2	21
162	Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma. <i>Annals of Oncology</i> , 2005, 16, 1849-1850.	0.6	21

#	ARTICLE	IF	CITATIONS
163	Internal Tandem Duplications of Flt3 Gene (Flt3/ITD) Predicts a Poor Post-Remission Outcome in Adult Patients with Acute Non-Promyelocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 73-78.	0.6	20
164	Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors in Multiple Myeloma: Study from the Italian Bone Marrow Donor Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 940-948.	2.0	20
165	Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Bone Marrow Transplantation</i> , 2017, 52, 955-961.	1.3	20
166	Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. <i>Leukemia Research</i> , 2012, 36, 607-618.	0.4	19
167	Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. <i>Digestive and Liver Disease</i> , 2007, 39, S129-S133.	0.4	18
168	Mesenchymal stem cells from JAK2V617F mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. <i>Leukemia Research</i> , 2008, 32, 516-517.	0.4	17
169	Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: The crucial role of PTEN. <i>Experimental Hematology</i> , 2009, 37, 1176-1185.e21.	0.2	17
170	BU/melphalan and auto-SCT in AML patients in first CR: a Gruppo Italiano Trapianto di Midollo Osseo (GITMO) retrospective study. <i>Bone Marrow Transplantation</i> , 2010, 45, 640-646.	1.3	17
171	Molecular Characterization of <i>Acinetobacter</i> Isolates Collected in Intensive Care Units of Six Hospitals in Florence, Italy, during a 3-Year Surveillance Program: a Population Structure Analysis. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1297-1304.	1.8	17
172	High recovery of mesenchymal progenitor cells with non-density gradient separation of human bone marrow. <i>Cytotherapy</i> , 2010, 12, 579-586.	0.3	17
173	The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo. <i>Human Pathology</i> , 2011, 42, 254-268.	1.1	17
174	Haematopoietic stem cell transplantation for autoimmune disorders. <i>Current Opinion in Hematology</i> , 2008, 15, 594-600.	1.2	16
175	Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. <i>Bone Marrow Transplantation</i> , 2015, 50, 505-510.	1.3	16
176	Unrelated donor marrow transplantation: an update of the experience of the Italian Bone Marrow Group (GITMO). <i>Haematologica</i> , 2001, 86, 451-6.	1.7	16
177	High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. <i>Bone Marrow Transplantation</i> , 2003, 31, 767-773.	1.3	15
178	Dose-Dense CHOP plus Rituximab (R-CHOP14) for the Treatment of Elderly Patients with High-Risk Diffuse Large B Cell Lymphoma: A Pilot Study. <i>Acta Haematologica</i> , 2006, 115, 22-27.	0.7	14
179	PET positivity with bone marrow biopsy revealing sarcoidosis in a patient in whom bone marrow metastases had been suspected. <i>British Journal of Haematology</i> , 2008, 143, 306-306.	1.2	14
180	The Role of Bortezomib, Thalidomide and Lenalidomide in the Management of Multiple Myeloma. <i>Pharmacoeconomics</i> , 2011, 29, 269-285.	1.7	14

#	ARTICLE	IF	CITATIONS
181	Human mesenchymal stromal cells preserve their stem features better when cultured in the Dulbecco's modified Eagle medium. <i>Cytotherapy</i> , 2011, 13, 539-548.	0.3	14
182	Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis. <i>Rheumatology</i> , 2012, 51, 1042-1048.	0.9	14
183	Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. <i>Leukemia</i> , 2012, 26, 1779-1785.	3.3	14
184	Risk of second cancers in chronic myeloproliferative neoplasms. <i>Blood</i> , 2012, 119, 3861-3862.	0.6	14
185	Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells. <i>Leukemia Research</i> , 2012, 36, 1290-1295.	0.4	14
186	Influence of the Jak2V617F Mutational Load at Diagnosis on Major Clinical Aspects in Patients with Polycythemia Vera.. <i>Blood</i> , 2006, 108, 5-5.	0.6	14
187	The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 88021-88033.	0.8	14
188	In situ immunologic characterization of cutaneous involvement in Hodgkin's disease. <i>Cancer</i> , 1989, 63, 661-666.	2.0	13
189	PET Scan Evaluation of Thymic Mass After Autologous Peripheral Blood Stem-cell Transplantation in an Adult with Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 2015-2018.	0.6	13
190	Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid. <i>Leukemia Research</i> , 2011, 35, 921-931.	0.4	13
191	Acquired severe aplastic anemia after H1N1 influenza virus vaccination successfully treated with allogeneic bone marrow transplantation. <i>Annals of Hematology</i> , 2012, 91, 475-476.	0.8	13
192	Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor. <i>Blood Transfusion</i> , 2013, 11, 94-101.	0.3	13
193	Inadequate erythropoietin production in allogeneic bone marrow transplant patients. <i>Haematologica</i> , 1991, 76, 280-4.	1.7	13
194	Hodgkin's Disease in the Elderly : A Retrospective Clinicopathologic Study of 61 Patients Aged over 60 Years. <i>Acta Haematologica</i> , 1987, 78, 163-170.	0.7	12
195	Molecular cytogenetic findings in a four-way t(1;12;5;12)(p36;p13;q33;q24) underlying the ETV6-PDGFRB fusion gene in chronic myelomonocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2007, 176, 67-71.	1.0	12
196	A policy for the disposal of autologous hematopoietic progenitor cells: report from an Italian consensus panel. <i>Transfusion</i> , 2014, 54, 2353-2360.	0.8	12
197	New patterns of relapse in multiple myeloma: a case of light chain escape in which FLC predicted relapse earlier than urine and serum immunofixation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 991-5.	1.4	12
198	Treatment of large cell lymphoma in elderly patients with a mitoxantrone, cyclophosphamide, etoposide, and prednisone regimen. <i>Cancer</i> , 2003, 97, 97-104.	2.0	11

#	ARTICLE	IF	CITATIONS
199	Inconsistencies in the association between the JAK2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases. <i>British Journal of Haematology</i> , 2006, 132, 652-654.	1.2	11
200	Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. <i>Blood</i> , 2007, 110, 4620-4621.	0.6	11
201	Stem cell transplantation for primary immunodeficiencies. <i>Bone Marrow Transplantation</i> , 2008, 41, S83-S86.	1.3	11
202	Dendritic cells with lymphocyte-stimulating activity differentiate from human CD133 positive precursors. <i>Blood</i> , 2011, 117, 3983-3995.	0.6	11
203	Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients. <i>Leukemia Research</i> , 2012, 36, 182-185.	0.4	11
204	CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia. , 2014, 86, 340-349.		11
205	Human herpesvirus 6-associated limbic encephalitis in adult recipients of unrelated umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2008, 42, 693-695.	1.3	10
206	Molecular analysis of population structure and antibiotic resistance of Klebsiella isolates from a three-year surveillance program in Florence hospitals, Italy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 371-378.	1.3	10
207	A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity score weighted multicenter approach. <i>American Journal of Hematology</i> , 2017, 92, E557-E559.	2.0	10
208	Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. <i>American Journal of Hematology</i> , 2018, 93, 1532-1542.	2.0	10
209	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1102-1109.	2.0	9
210	Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2005, 103, 970-977.	2.0	8
211	The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: Results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Societ� Italiana di Emaferesi e Manipolazione Cellulare (SidEM) survey. <i>Transfusion and Apheresis Science</i> . 2013, 49, 615-622.	0.5	8
212	Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2014, 55, 781-785.	0.6	8
213	The circadecadal rhythm of oscillation of umbilical cord blood parameters correlates with geomagnetic activity – An analysis of long-term measurements (1999–2011). <i>Chronobiology International</i> , 2016, 33, 1136-1147.	0.9	8
214	Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. <i>Blood Advances</i> , 2020, 4, 301-311.	2.5	8
215	The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms.. <i>Blood</i> , 2009, 114, 2914-2914.	0.6	8
216	No role for CXCL12 –G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia. <i>Leukemia</i> , 2008, 22, 669-671.	3.3	7

#	ARTICLE	IF	CITATIONS
217	OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING REDUCED-INTENSITY CONDITIONING REGIMEN IN PATIENTS WITH IDIOPATHIC MYELOFIBROSIS: THE G.I.T.M.O. EXPERIENCE AND REVIEW OF THE LITERATURE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010010.	0.5	7
218	A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84B, 71-81.	0.7	7
219	Treatment of experimental esophagogastric myotomy with bone marrow mesenchymal stem cells in a rat model. <i>Neurogastroenterology and Motility</i> , 2013, 25, e669-79.	1.6	7
220	Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2071-2078.	0.6	7
221	High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 475-481.	2.0	7
222	Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 22-32.	1.4	7
223	“Best practice” for extracorporeal photopheresis in acute and chronic graft-versus-host disease by Società Italiana di Emaferesi and Manipolazione Cellulare and Gruppo Italiano Trapianto Midollo Osseo: a national survey to ascertain its degree of application in Italian transplant centers. <i>Transfusion</i> , 2018, 58, 217-222.	0.8	7
224	Inhibitors of PI3K/Akt and/or mTOR Inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 Inhibitor and Interferon. <i>Blood</i> , 2011, 118, 3835-3835.	0.6	7
225	PKRD: a pharmacokinetic program for least-squares and bayesian analysis of repeated-dose pharmacokinetic curves. <i>Computer Methods and Programs in Biomedicine</i> , 1992, 38, 27-35.	2.6	6
226	Treatment options for essential thrombocythemia and polycythemia vera. <i>Expert Review of Hematology</i> , 2009, 2, 41-55.	1.0	6
227	Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey. <i>Cytotherapy</i> , 2014, 16, 101-110.	0.3	6
228	Primary Conjunctival Lymphoma: Response to Chemotherapy in 4 Cases. <i>Acta Haematologica</i> , 1982, 68, 161-162.	0.7	5
229	One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment. <i>Blood</i> , 2019, 134, 2231-2231.	0.6	5
230	<i>Candida krusei</i> fungemia in an unrelated allogeneic hematopoietic stem cell transplant patient successfully treated with Caspofungin. <i>Bone Marrow Transplantation</i> , 2005, 35, 1215-1216.	1.3	4
231	<i>Pseudomonas aeruginosa</i> Sepsis in Stem Cell Transplantation Patients. <i>Infection Control and Hospital Epidemiology</i> , 2006, 27, 767-770.	1.0	4
232	Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1044-1048.	0.6	4
233	Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia. <i>Experimental Hematology</i> , 2015, 43, 869-879.e22.	0.2	4
234	The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 413.	1.6	4

#	ARTICLE	IF	CITATIONS
235	Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category. <i>Cancers</i> , 2020, 12, 3196.	1.7	4
236	IHP Interpretation Criteria of Interim-PET Scan Confirms Prognostic Impact In Early Stage Hodgkin Lymphoma Patients without Bulky Disease. <i>Blood</i> , 2010, 116, 3890-3890.	0.6	4
237	Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis. <i>Blood</i> , 2011, 118, 2811-2811.	0.6	4
238	Unrelated donor marrow transplantation: an update of the experience of the Italian Bone Marrow Transplant Group (GITMO). <i>Haematologica</i> , 2000, 85, 30-6.	1.7	4
239	Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia. <i>Cancer</i> , 2007, 109, 343-343.	2.0	3
240	Immunohistochemical and FISH analyses identify synovitis associated with chronic GVHD after allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2008, 42, 289-291.	1.3	3
241	Pulmonary mucormycosis with cervical lymph node involvement in a patient with acute myeloid leukaemia: a case report. <i>Mycoses</i> , 2008, 51, 354-356.	1.8	3
242	Molecular Surveillance and Population Structure Analysis of Methicillin-Susceptible and Methicillin-Resistant <i>Staphylococcus aureus</i> in High-Risk Wards. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3246-3254.	1.8	3
243	Atypical Acute Leukemia Early After Liver Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 3945-3946.	0.3	3
244	Haematopoietic stem cell transplantation: a comparison between the accreditation process performed by competent authorities and JACIE in Italy. <i>Vox Sanguinis</i> , 2013, 105, 174-176.	0.7	3
245	Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen. <i>Supportive Care in Cancer</i> , 2014, 22, 2557-2561.	1.0	3
246	Skin CD30+ T cells and circulating levels of soluble CD30 are increased in patients with graft versus host disease. <i>Autoimmunity Highlights</i> , 2014, 5, 21-26.	3.9	3
247	The use of Deauville 5-point score could reduce the risk of false-positive fluorodeoxyglucose-positron emission tomography in the posttherapy evaluation of patients with primary bone lymphomas. <i>World Journal of Nuclear Medicine</i> , 2018, 17, 157-165.	0.3	3
248	Phenotypic and Ultrastructural Profile of M5 Leukemia Cells in Peripheral Blood and Skin Infiltrate. <i>Tumori</i> , 1986, 72, 63-69.	0.6	2
249	Aztreonam versus Colistin-Neomycin for Selective Decontamination of the Digestive Tract in Patients Undergoing Bone Marrow Transplantation: a Randomized Study. <i>Journal of Chemotherapy</i> , 1992, 4, 30-34.	0.7	2
250	An Open Evaluation of Triple Antibiotic Therapy Including Vancomycin for Febrile Bone Marrow Transplant Recipients with Severe Neutropenia. <i>Journal of Chemotherapy</i> , 1999, 11, 287-292.	0.7	2
251	Long-term follow-up of concomitant treatment with romiplostim and warfarin in a patient with immune thrombocytopenia and severe cardiac comorbidities. <i>Platelets</i> , 2013, 24, 242-243.	1.1	2
252	Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey. <i>Journal of Blood Medicine</i> , 2018, Volume 10, 21-27.	0.7	2

#	ARTICLE	IF	CITATIONS
253	Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1387-1394.	2.0	2
254	Rosiglitazone promotes the differentiation of Langerhans cells and inhibits that of other dendritic cell types from CD133 positive hematopoietic precursors. <i>Histology and Histopathology</i> , 2014, 29, 323-32.	0.5	2
255	Neutral maltase of human granulocytes: Localization on the extracytoplasmic side of the plasma membrane and some properties. <i>Biochemical Medicine and Metabolic Biology</i> , 1988, 40, 186-196.	0.7	1
256	PROGNOSTIC FACTORS IN HODGKIN'S DISEASE. <i>Lancet</i> , The, 1988, 331, 1117.	6.3	1
257	Recombinant Human Erythropoietin: Clinical Experience in Bone Marrow Transplantation. <i>Leukemia and Lymphoma</i> , 1992, 7, 97-98.	0.6	1
258	JAK2V617F mutation screening in patients with retinal vein thrombosis or recurrent fetal loss. <i>Thrombosis Research</i> , 2009, 124, 377-378.	0.8	1
259	Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome. <i>Annals of Hematology</i> , 2010, 89, 745-746.	0.8	1
260	Impact of Dose-Dense Immunochemotherapy on Prognosis of Germinal Center and Non Germinal Center Origin of Diffuse Large B Cell Lymphoma. <i>Journal of Chemotherapy</i> , 2011, 23, 227-231.	0.7	1
261	Romiplostim before splenectomy in a patient with aggressive non-Hodgkin lymphoma and poor response to platelet transfusions. <i>Transfusion Medicine</i> , 2014, 24, 125-126.	0.5	1
262	Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide. <i>Leukemia and Lymphoma</i> , 2015, 56, 2388-2391.	0.6	1
263	Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1304-1313.	2.0	1
264	Imatinib as Salvage Therapy for Patients with Refractory cGVHD: the Interim Analysis of the Prospective GITMO* Multicenter Study*Gruppo Italiano Trapianto Di Midollo Osseo.. <i>Blood</i> , 2009, 114, 3558-3558.	0.6	1
265	Response Assessment After Induction Therapy in Diffuse Large B Cell Lymphoma (DLBCL): Role of Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) in Comparison with Computed Tomography (CT).. <i>Blood</i> , 2009, 114, 4995-4995.	0.6	1
266	Treatment with Ruxolitinib (INC018424) Induced Changes of Microrna Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia,. <i>Blood</i> , 2011, 118, 3852-3852.	0.6	1
267	Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8040-8040.	0.8	1
268	The Association of a Salvage Treatment Containing Novel Agents Followed by Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning Regimen Improves Overall Survival and Time-to-Progression in Multiple Myeloma Patients Relapsing After Autologous Stem Cell Transplantation: A Multicentric Retrospective Study Based On Donor Availability.. <i>Blood</i> , 2009, 114, 4320-4320.	0.6	1
269	Serum TARC Concentration Kinetic in Classical Hodgkin Lymphoma during First-Line Treatment. <i>Blood</i> , 2021, 138, 4500-4500.	0.6	1
270	Antiemetic Prophylaxis in Patients Undergoing Bone Marrow Transplantation: The Role of Ondansetron. <i>Leukemia and Lymphoma</i> , 1992, 7, 90-91.	0.6	0



#	ARTICLE	IF	CITATIONS
271	C003 Proliferative and apoptotic signalling in bone marrow cell subpopulations of myelodysplastic syndromes patients using flow-cytometry technique. <i>Leukemia Research</i> , 2009, 33, S32.	0.4	0
272	P117 Monocentric evaluation of response and tolerability of subcutaneous azacitidine in elderly MDS patients with comorbidities. <i>Leukemia Research</i> , 2009, 33, S127-S128.	0.4	0
273	Romiplostim overcomes refractory secondary immune thrombocytopenia in a patient affected by serous ovarian carcinoma. <i>International Cancer Conference Journal</i> , 2012, 1, 239-242.	0.2	0
274	Diagnosis of a T-lineage acute lymphoblastic leukemia through digitalized cell analysis of the pleural effusion. <i>International Medical Case Reports Journal</i> , 2013, 6, 77.	0.3	0
275	Chemotherapy-related nail toxicity. <i>International Journal of Hematology</i> , 2019, 110, 519-520.	0.7	0
276	Non-scarring patchy alopecia: What else, apart from alopecia areata?. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 1282-1285.	0.7	0
277	First Line Treatment with Rituximab and Chlorambucil in the Treatment of Ocular Adnexal Lymphomas.. <i>Blood</i> , 2006, 108, 4712-4712.	0.6	0
278	Liposomal Doxorubicin in the Treatment of Elderly, Cardiopatic, or Pretreated Patients with Aggressive Lymphomas: Comparison with an Historical Series.. <i>Blood</i> , 2006, 108, 4685-4685.	0.6	0
279	Hepcidin Levels and Their Determinants In Different Types of Myelodysplastic Syndromes. <i>Blood</i> , 2010, 116, 4250-4250.	0.6	0
280	High-Dose Rituximab in the Conditioning Regimen Before Allogeneic Stem Cell Transplantation Reduces the Incidence of Acute Gvhd in B-Cell Lymphomas. <i>Blood</i> , 2011, 118, 4546-4546.	0.6	0
281	A randomized double-blind phase III pivotal study of febuxostat (FEB) versus allopurinol (ALL) in the prevention of tumor lysis syndrome (TLS): Florence study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9641-9641.	0.8	0
282	Underestimated Needs for Lymphoma Patients: An Assessment Issue.. <i>Acta Biomedica</i> , 2022, 93, e2022147.	0.2	0